Cybin initiates phase 2 proof-of-concept study of cyb004 in generalized anxiety disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the initiation of a phase 2 proof-of-concept study of cyb004, its proprietary dmt molecule in development for the treatment of gad. in january 2024, the u.s. food and drug administration (“fda”) cleared cyb.
CYBN Ratings Summary
CYBN Quant Ranking